PCRX Pacira BioSciences, Inc.

$25.84

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.

Website: https://www.pacira.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1396814
Address
5 SYLVAN WAY, SUITE 300, PARSIPPANY, NJ, US
Valuation
Market Cap
$1.14B
P/E Ratio
nan
PEG Ratio
-3.83
Price to Book
1.47
Performance
EPS
$-2.15
Dividend Yield
—
Profit Margin
-14.20%
ROE
-12.10%
Technicals
50D MA
$24.62
200D MA
$19.72
52W High
$31.67
52W Low
$11.16
Fundamentals
Shares Outstanding
46M
Target Price
$36.00
Beta
0.71

PCRX EPS Estimates vs Actual

● Estimated
● Actual

PCRX News & Sentiment

Aug 06, 2025 • Motley Fool NEUTRAL
Pacira ( PCRX ) Q2 Revenue Rises 1.7%
Pacira BioSciences ( NASDAQ:PCRX ) is a specialty pharmaceutical company known for its non-opioid pain management products. On August 5, 2025, it reported financial results for the quarter. The headline results showed non-GAAP earnings per share of $0.74, beating analyst consensus by 4.2% ( ...
Jul 25, 2025 • Business Insider BULLISH
PRSA-NY Big Apple Awards Winners Shortlist Announced and Tickets Now Available for the 2025 Gala
NEW YORK, July 25, 2025 ( GLOBE NEWSWIRE ) -- PRSA-NY has officially unveiled today the shortlist for the 2025 Big Apple Awards, celebrating excellence in public relations across the New York area.
Jul 24, 2025 • Benzinga NEUTRAL
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025 - Pacira BioSciences ( NASDAQ:PCRX )
BRISBANE, Calif., July 24, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. PCRX, the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter financial results after the close ...
Jul 03, 2025 • GlobeNewswire NEUTRAL
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BRISBANE, Calif., July 03, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc. ( Nasdaq: PCRX ) , the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new ...
Jun 18, 2025 • Zacks Commentary NEUTRAL
Is the Options Market Predicting a Spike in Pacira BioSciences Stock?
Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
Jun 18, 2025 • Benzinga NEUTRAL
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient's Journey to Pain Relief and Innovation in Care at BIO 2025 - Pacira BioSciences ( NASDAQ:PCRX )
- Produced for Pacira by BBC StoryWorks Commercial Productions, The Next Frontier: Mark & Leah's Story Highlights the Impact of Non-Opioid Solutions - BRISBANE, Calif., June 18, 2025 ( GLOBE NEWSWIRE ) -- Pacira BioSciences, Inc.
Sentiment Snapshot

Average Sentiment Score:

0.085
50 articles with scored sentiment

Overall Sentiment:

Neutral

PCRX Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Feb 26, 2025
Dec 31, 2024 (Pre market)
0.08 Surprise
  • Reported EPS: $0.91
  • Estimate: $0.83
  • Whisper: —
  • Surprise %: 9.6%
Nov 06, 2024
Sep 30, 2024 (Post market)
0.09 Surprise
  • Reported EPS: $0.79
  • Estimate: $0.70
  • Whisper: —
  • Surprise %: 12.9%
Jul 30, 2024
Jun 30, 2024 (Post market)
0.19 Surprise
  • Reported EPS: $0.89
  • Estimate: $0.70
  • Whisper: —
  • Surprise %: 27.1%
May 07, 2024
Mar 31, 2024 (Post market)
0.0 Surprise
  • Reported EPS: $0.62
  • Estimate: $0.62
  • Whisper: —
  • Surprise %: 0.0%
Feb 29, 2024
Dec 31, 2023 (Pre market)
0.01 Surprise
  • Reported EPS: $0.89
  • Estimate: $0.88
  • Whisper: —
  • Surprise %: 1.1%
Nov 02, 2023
Sep 30, 2023 (Pre market)
-0.06 Surprise
  • Reported EPS: $0.72
  • Estimate: $0.78
  • Whisper: —
  • Surprise %: -7.7%
Aug 02, 2023
Jun 30, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $0.78
  • Estimate: $0.76
  • Whisper: —
  • Surprise %: 2.6%
May 03, 2023
Mar 31, 2023 (Pre market)
-0.09 Surprise
  • Reported EPS: $0.53
  • Estimate: $0.62
  • Whisper: —
  • Surprise %: -14.5%

Financials